In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I […]readmore
Tags : Durect
The US FDA has approved 7 NDAs and 1 BLA in Feb 2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation […]readmore
Shots: The approval is based on clinical trial involves assessing Posimir (4mg) vs PBO (12mg) in patients in patients undergoing arthroscopic subacromial decompression surgery with an intact rotator cuff for […]readmore
Shots: Durect to receive $25M up front, ~$145M milestones including ~$75M for development & regulatory and ~$70M on sales plus royalties on sales of products. Gilead to get exclusive WW […]readmore